Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. This episode walks us through the initial research that ...

The GATHER1 and GATHER2 studies are highlighted. Ryan Haumschild, PharmD, MS, MBA: We know that avacincaptad pegol, or ACP, is one of the coming complement inhibitors that’s being evaluated for use in ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s ...

Undertaking a study of proteins found in the complement system, an important part of the immune system, of patients with long COVID, researchers have identified a blood protein ‘signature’ that may ...

A new study shows that the complement system, part of the innate immune system, plays a protective role to slow retinal degeneration in a mouse model of retinitis pigmentosa, an inherited eye disease.